Pharmaceuticals News and Research

RSS

Eagle Pharmaceuticals and USAMRICD signs agreement to assess neuroprotective effects of RYANODEX

Eagle Pharmaceuticals, Inc. today announced that it has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense, the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development, to conduct a study to evaluate the neuroprotective effects of RYANODEX.

3 Oct 2018

VA adding opioid antidote to defibrillator cabinets for quicker overdose response

It took more than 10 minutes for paramedics to arrive after a housekeeper found a man collapsed on the floor of a bathroom in a Boston Veteran Affairs building.

3 Oct 2018

New search technique efficiently identifies antibiotic compounds

If you're looking for a needle in a haystack, it's best to know what hay looks like. An international team of researchers has applied this idea to the search for new pharmaceuticals, developing a technique that reduces the chances of simply rediscovering known compounds.

3 Oct 2018

Spero Health launched to tackle the rising opioid crisis

Spero Health, Inc., a newly formed healthcare organization specializing in local, affordable, outpatient care for individuals suffering from substance use disorder, announced that it has acquired investment growth capital to meet the demand in communities across the country for high-quality, comprehensive and integrated addiction treatment services.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

Scientists at The Wistar Institute have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.

28 Sep 2018

New combination therapy shows potential in treating incurable HPV-related cancers

A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Workers overdose on the job, and employers struggle to respond

Jimmy Sullivan prepared for his job as a bricklayer the same way every morning for years: injecting a shot of heroin before leaving his car.

28 Sep 2018

Buried in Congress’ opioid bill is protection for personal drug imports

The final version of the massive opioid bill Congress released Wednesday would grant the Food and Drug Administration new powers to crack down on drug imports, but it also includes a provision — nearly killed in the Senate — to shield people who are just trying to buy cheaper, needed prescription medication from other countries.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Natural wood-based bioactive substances combat antimicrobial resistance in hospitals

A recently launched development project called Sami&Samu is looking to introduce innovative renewable materials, surface finishes and textiles to Hospital Nova, a new hospital due to open in Central Finland in 2020.

27 Sep 2018

GARDP partners with Novartis to accelerate development of generic antibiotic treatments for children

The Global Antibiotic Research & Development Partnership and Novartis are joining forces to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries.

27 Sep 2018

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson's disease psychosis -- a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions -- researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin, did not pose a statistically significant greater risk of death.

27 Sep 2018

Digital CBT can improve insomnia symptoms, daytime functioning and overall health

Treating insomnia with digital programs can improve insomnia symptoms, daytime functioning and overall health, a new study from the University of Oxford and Northwestern Medicine has found.

26 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

Columbia University has decided to award the Louisa Gross Horwitz Prize 2018.

24 Sep 2018

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Pharmaceuticals News and Research

Eagle Pharmaceuticals and USAMRICD signs agreement to assess neuroprotective effects of RYANODEX

VA adding opioid antidote to defibrillator cabinets for quicker overdose response

New search technique efficiently identifies antibiotic compounds

Spero Health launched to tackle the rising opioid crisis

Alnylam reports further progress on broadening the therapeutic potential of RNAi

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

Synthetic DNA vaccine targets proteins overexpressed in several types of cancer

New combination therapy shows potential in treating incurable HPV-related cancers

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Workers overdose on the job, and employers struggle to respond

Buried in Congress’ opioid bill is protection for personal drug imports

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Natural wood-based bioactive substances combat antimicrobial resistance in hospitals

GARDP partners with Novartis to accelerate development of generic antibiotic treatments for children

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

Digital CBT can improve insomnia symptoms, daytime functioning and overall health

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Columbia University announces winners of 2018 Louisa Gross Horwitz Prize

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring